Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm(3) and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
Gervasoni
Cristina
C
Clinical Science Department, Section of Infectious Diseases, University of Milan, L Sacco Hospital, Via GB Grassi 74 20157 Milan, Italy. cristina.gervasoni@unimi.it.
Vigano
Ottavia
O
Grinelli
Erika
E
Ortu
Massimiliano
M
Galli
Massimo
M
Rusconi
Stefano
S
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D010078:Oxazines / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019259:Lamivudine; D010078:Oxazines; D012367:RNA, Viral; D000099227:Abacavir; C098320:efavirenz